A Preliminary Evaluation on the Antifungal Efficacy of VT-1161 against Persister ICandida albicans/I Cells in Vulvovaginal Candidiasis

• Published in: Biomedicines Vol. 12; no. 2
• Main Authors: Sinoca, Marica, Maione, Angela, Gambino, Edvige, Imparato, Marianna, Galdiero, Marilena, de Alteriis, Elisabetta, Galdiero, Emilia, Guida, Marco
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.02.2024
• Subjects: Antifungal agents; Candidiasis, Vulvovaginal; Cells; Enzymes; Ethylenediaminetetraacetic acid; Triazoles; Germany; Missouri
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12020389

Persister cells are a small fraction of the microbial population that survive lethal concentrations of antimicrobial agents. Candida albicans causes vaginal candidiasis, including recurrent vulvovaginal candidiasis, and may survive common antifungal treatments. The triazole VT-1161 is an antifungal agent that specifically targets fungal CYP51, as opposed to the human CYP enzyme. This work illustrates a new role of VT-1161 in eradicating the biofilm created from the persister cells of a primary biofilm of a clinical vaginal isolate of C. albicans. Antifungal activity was determined by the minimum inhibitory concentration (MIC), and the primary biofilm was treated with amphotericin B to obtain persister cells that were able to form a new biofilm. Results obtained using the new azole VT-1161 showed that VT-1161 not only eradicated a secondary biofilm formed from the persister-derived biofilm and counteracted the adhesion of C. albicans in vitro to human cells but also ameliorated C. albicans-induced infection in vivo in Galleria mellonella larvae, suggesting that it could be proposed as an alternative therapeutic strategy for the treatment of recurrent candidiasis.